Pierre Fabre renews Indian partnership

Published: 4-Mar-2015

The French pharmaceutical group has renewed its partnership with Abbott Healthcare

French pharmaceutical group and dermo-cosmetics laboratory Pierre Fabre has renewed its partnership with Abbott Healthcare, one of India's largest pharmaceutical and health care companies.

The partnership concerns the commercialisation in India of Pierre Fabre brands Avéne, Ducray and A-Derma. Together, the brands' combined product ranges cover cleansing, moisturising, anti-ageing, anti-acne, sun protection, hyper-pigmentation and healing treatments for atopic and sensitive skins.

"Abbott's partnership with Pierre Fabre shows our commitment to bring to India globally renowned dermo-cosmetic formulations. Its globally popular brands address multitudes of skin concerns of people with sensitive skin or irritated skin; and preserving health and beauty of normal skin and hair," said Sudarshan Jain, Managing Director of Abbott Healthcare.

"Pierre Fabre's background as a pharmaceutical company specialising in dermatology in addition to its French know-how of cosmetic formulation is completed with a high knowledge of the Indian market through our association with Abbott," commented Eric Ducournau, Chairman of Pierre Fabre. "In order to fulfil the highest expectations of sensitive or fragile skins, clinical and consumer tests have been performed internationally but also locally to show efficiency and acceptation of our formulations on Indian skin," he added.

Commenting on its plans in the Indian market, Pierre Benham, Country Head of Indian Operation, said: "The dermo-cosmetic market in India is fairly new but has a lot of potential. The current market size can be pegged at around €100m (rs700 crores) within five years. We have plans to launch six new types of products per year, and are therefore confident that our premium brands will be instrumental to convert this potential."

Pierre Fabre products are currently available at chemist stores across India.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
  2. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like